Late Thursday the companies touted biomarker data from an early-stage study that showed the drug lowered the disease-causing protein in people with the disease. Source: BioSpace

Biogen and AbbVie have voluntarily pulled their Zinbryta for relapsing multiple sclerosis (MS) off the market after safety concerns. Source: BioSpace

Sorrento Therapeutics, Inc. nabbed regulatory approval for ZTlido, a non-opioid pain treatment in the form of a super-sticky patch. Source: BioSpace

Shares of Portola Pharmaceuticals are falling after the company announced a delay of several months for possible regulatory approval of its Factor Xa-inhibitor antidote, AndexXa. Source: BioSpace

Finch Therapeutics closed on an oversubscribed Series B financing worth $36 million. Source: BioSpace

Rubius Therapeutics has closed on an oversubscribed $100 million crossover financing. Source: BioSpace

Mylan N.V. signed a global collaboration and license deal with Revance Therapeutics to develop and market a biosimilar to Botox. Source: BioSpace

Boston-based Gelesis snagged $30 million to support potential manufacturing and commercialization of its anti-obesity drug. Source: BioSpace

With no end to the national opioid crisis in sight, the U.S. Department of Justice announced a plan to form a task force that will target opioid manufacturers and distributors.…

Gene-editing company Inscripta, formerly known as Muse Biotechnologies, will be able to expand its research capabilities and increase hiring after the company closed a Series C funding round of $55.5…